ADMA
Plot twist: now comes the lawyers
ADMA Biologics is back in the spotlight, but not for a breakthrough drug or a shiny earnings beat. Rosen Law Firm says it’s investigating potential securities claims on behalf of shareholders, arguing ADMA may have issued materially misleading business info to the market.
Why investors should care
This is the kind of story that can keep the stock in the penalty box. A class-action investigation doesn’t automatically mean wrongdoing, but it does mean more uncertainty, more headline risk, and the possibility of ugly legal costs down the road.
The short-seller cloud is still hanging around
The complaint isn’t coming out of nowhere. The firm points to a March 24, 2026 article that said ADMA shares plunged after Culper Research accused the company of channel stuffing to make revenue growth look better than it really was. The stock reportedly fell 16.6% that day, which is the market’s version of saying, “Yeah, we’re listening.”
Big picture
For investors, the issue isn’t just whether ADMA can win in court. It’s whether this story keeps distracting from the actual business and compresses the stock’s multiple until the legal dust settles. In other words: fun times for lawyers, not so fun times for shareholders.